Jennifer R Stark

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Factors associated with colorectal cancer risk perception: the role of polyps and family history
    Jennifer Rider Stark
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Health Educ Res 21:740-9. 2006
  2. ncbi Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study
    Jennifer R Stark
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    J Natl Cancer Inst 101:1406-11. 2009
  3. ncbi Toll-like receptor signaling pathway variants and prostate cancer mortality
    Jennifer R Stark
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1859-63. 2009
  4. ncbi Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
    Jennifer R Stark
    ScD, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 27:3459-64. 2009
  5. ncbi Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality
    Jennifer Rider Stark
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 124:2683-9. 2009
  6. ncbi Genetic variation in RNASEL associated with prostate cancer risk and progression
    Mara S Meyer
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Carcinogenesis 31:1597-603. 2010
  7. ncbi mRNA expression signature of Gleason grade predicts lethal prostate cancer
    Kathryn L Penney
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 29:2391-6. 2011
  8. ncbi Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study
    Lorelei A Mucci
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 125:1143-6. 2009
  9. ncbi Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort
    Lorelei A Mucci
    Channing Laboratory, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:1682-8. 2008
  10. ncbi Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality
    Irene M Shui
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Prostate 72:209-16. 2012

Detail Information

Publications12

  1. ncbi Factors associated with colorectal cancer risk perception: the role of polyps and family history
    Jennifer Rider Stark
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Health Educ Res 21:740-9. 2006
    ..Potential interactions between objective risk factors and socioeconomic characteristics should be further explored in longitudinal studies...
  2. ncbi Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study
    Jennifer R Stark
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    J Natl Cancer Inst 101:1406-11. 2009
    ..We confirmed these findings in an independent population and related serostatus for antibodies against T vaginalis to prostate cancer incidence and mortality...
  3. ncbi Toll-like receptor signaling pathway variants and prostate cancer mortality
    Jennifer R Stark
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1859-63. 2009
    ..No significant associations were observed for common haplotypes and PCa mortality. This study highlights the importance of studies of PCa mortality because risk factors for incidence and mortality may differ...
  4. ncbi Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
    Jennifer R Stark
    ScD, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 27:3459-64. 2009
    ..82; biopsy C-statistic, 0.72). CONCLUSION Ignoring the predominance of Gleason pattern 4 in GS 7 cancers may conceal important prognostic information. A standardized review of GS can improve prediction of PCa survival...
  5. ncbi Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality
    Jennifer Rider Stark
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 124:2683-9. 2009
    ..02). Adjusted hazard ratios were 1.73 (95% CI: 0.86, 3.51) comparing the highest to lowest IL-6 level. Our study suggests that IL-6 may potentially be involved in the development or progression of prostate cancer...
  6. ncbi Genetic variation in RNASEL associated with prostate cancer risk and progression
    Mara S Meyer
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Carcinogenesis 31:1597-603. 2010
    ..The results of this study support a link between RNASEL and prostate cancer and suggest that the association may be mediated through inflammation. These novel findings warrant replication in future studies...
  7. ncbi mRNA expression signature of Gleason grade predicts lethal prostate cancer
    Kathryn L Penney
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 29:2391-6. 2011
    ....
  8. ncbi Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study
    Lorelei A Mucci
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 125:1143-6. 2009
    ..However, our data indicate that prostate cancer cases who carry the variant N allele are more likely to be overweight, and may be more susceptible to the angiogenic influences of obesity in prostate cancer pathogenesis...
  9. ncbi Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort
    Lorelei A Mucci
    Channing Laboratory, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:1682-8. 2008
    ..78) than the clinical model alone (area under the curve = 0.71; P = 0.04). Molecular tumor markers can add to clinical variables to help distinguish lethal and indolent prostate cancer and hold promise to guide treatment decisions...
  10. ncbi Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality
    Irene M Shui
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Prostate 72:209-16. 2012
    ..Common genetic variants in the Toll-like receptor 4 (TLR4), which is involved in inflammation and immune response pathways, may be important for prostate cancer...
  11. ncbi Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:484-91. 2010
    ..Given the role of the IGF system in prostate cancer, ALS may influence carcinogenesis by modulating IGF-I levels or bioavailability...
  12. ncbi Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:249-51. 2008
    ..We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer...